非酒精性脂肪性肝病合并2型糖尿病患者外周血miR-17、miR-20a和miR-20b变化及其临床意义*

doi:10.3969/j.issn.1672-5069.2021.05.023

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者外周血miR-17、miR-20a和miR-20b变化及其临床意义。方法 2018年12月～2020年6月我院收治的T2DM患者46例和NAFLD合并T2DM患者50例(轻度19例、中度17例和重度14例)。采用实时荧光定量RT-PCR法检测血清miR-17、miR-20a和miR-20b mRNA水平。采用多因素Logistic回归分析NAFLD合并T2DM发生的独立危险因素,应用受试者工作特征曲线(ROC)下面积(AUC)分析各指标诊断严重NAFLD的效能。结果 NAFLD合并T2DM患者外周血miR-17、miR-20a和miR-20b mRNA水平分别为(5.6±1.3)、(3.8±0.9)和(1.8±0.5),显著高于T2DM患者【分别为(4.4±1.1)、(3.1±0.6)和(1.4±0.4),P<0.05】;重度NAFLD组血清miR-17、miR-20a和miR-20b mRNA水平分别为(6.0±1.1)、(4.0±0.8)和(1.9±0.5),显著高于中度患者【分别为(4.4±1.0)、(3.4±0.6)和(1.5±0.4),P<0.05】或轻度患者【分别为(4.1±0.6)、(2.8±0.8)和(1.2±0.3),P<0.05】;多因素Logistic回归分析显示,BMI、血清LDL-C、miR-17、miR-20a和miR-20b是NAFLD合并T2DM发生的独立危险因素(P<0.05);ROC分析结果显示,血清miR-17、miR-20a和miR-20b诊断严重NAFLD的AUC分别为0.75、0.74和0.70。结论 NAFLD合并T2DM患者外周血miR-17、miR-20a和miR-20b水平显著升高,可能参与了NAFLD的发病过程,对判断NAFLD的严重程度具有一定的意义。

关键词: 非酒精性脂肪肝病, 2型糖尿病, miR-17, miR-20a, miR-20b, 诊断

Abstract: Objective The aim of this study was to explore the implications of serum micro RNA (miR)-17, miR-20a and miR-20b in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Methods 46 patients with T2DM and 50 patients (mild in 19, moderate in 17 and severe in 14) with NAFLD and T2DM were admitted to our hospital between December 2018 and June 2020. Serum miR-17, miR-20a and miR-20b mRNA levels were detected by real-time fluorescent quantitative RT-PCR. Multivariate Logistic regression analysis was applied to analyze the independent risk factorsfor occurrence of T2DM with underlying NAFLD, and the area (AUC) under the receiver operating characteristic curve (ROC) was applied to analyze the diagnostic efficacy of each indicator for severe NAFLD. Results Serum miR-17, miR-20a and miR-20b mRNA levels in patients with NAFLD and T2DM were (5.6±1.3),(3.8±0.9) and (1.8±0.5), all significantly higher than in patients with T2DM; serum miR-17, miR-20a and miR-20b mRNA levels in patients with severe NAFLD were (6.0±1.1), (4.0±0.8) and (1.9±0.5), significantly higher than in patients with moderate NAFLD or in patients with mild NAFLD; multivariate Logistic regression analysis showed that the body mass index, serum LDL-C, miR-17, miR-20a and miR-20b levels were the independent risk factors for T2DM with underlying NAFLD (P<0.05); the ROC analysis demonstrated that the AUC were 0.75, 0.74 and 0.70 by serum miR-17, miR-20a and miR-20b in diagnosing severe NAFLD. Conclusion Serum miR-17, miR-20a and miR-20b levels in patients with NAFLD and T2DM significantly increase, which might be involved in the pathogenesis of NAFLD.

Key words: Non-alcoholic fatty liver diseases, Type 2 diabetes mellitus, micro RNA-17, miR-20a, miR-20b, Diagnosis

葛海燕, 匡霞, 周瑞君. 非酒精性脂肪性肝病合并2型糖尿病患者外周血miR-17、miR-20a和miR-20b变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(5): 697-700.

Ge Haiyan, Kuang Xia, Zhou Ruijun. Changes of serum miR-17, miR-20a and miR-20b levels in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus[J]. Journal of Practical Hepatology, 2021, 24(5): 697-700.

参考文献

[1]Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care, 2017,40(3):419-430.
[2]Mantovani A, Byrne CD, Bonora E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care,2018,41(2):372-382.
[3]Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (e-lift trial). Diabetes Care,2018,41(8):1801-1808.
[4]梁苡菲,匡洪宇,秦文,等.中国北方地区2型糖尿病患者摄盐量与非酒精性脂肪性肝病的相关性.中华老年多器官疾病杂志,2019,18(10):765-768.
[5]邵幼林,范建高.非酒精性脂肪性肝病的流行现状与危害.中华肝脏病杂志,2019,27(1):10-13.
[6]张智慧,陈明云,柯蒋风,等.老年2型糖尿病患者餐后2小时血糖与空腹血糖差值和非酒精性脂肪性肝病的相关性研究.中华老年医学杂志,2020,25(4):395-398.
[7]Del CJA, Gallego DR, Gallego P, et al. Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). Int J Mol Sci,2018,19(3):911.
[8]Torres JL, Novo-Veleiro I, Manzanedo L, et al. Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease. World J Gastroenterol,2018,24(36):4104-4118.
[9]中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会,范建高,等.非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(02):177-186.
[10] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版).中华糖尿病杂志,2018,10(1):4-67.
[11] 阎劲松,袁丹,李东升.影响2型糖尿病患者新发非酒精性脂肪肝相关因素分析.实用肝脏病杂志,2016,19(2):212-214.
[12] Hosny SS, Ali HM, Mohammed WA, et al. Study of relationship between total vitamin D level and NAFLD in a sample of Egyptian patients with and without T2DM. Diabetes Metab Syndr, 2019,13(3):1769-1771.
[13] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology,2019,69(6):2672-2682.
[14] Rhee EJ. Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective. Endocrinol Metab (Seoul),2019,34(3):226-233.
[15] Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut,2017,66(6):1138-1153.
[16] Scorletti E, Byrne CD. Extrahepatic diseases and NAFLD: The triangular relationship between NAFLD, type 2-diabetes and dysbiosis. Dig Dis,2016,34:11-18.
[17] Liu CH, Ampuero J, Gil GA, et al. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol,2018,69(6):1335-1348.
[18] Ye D, Zhang T, Lou G, et al. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. Life Sci, 2018,208:201-207.
[19] Ye D, Lou G, Zhang T, et al. MiR-17 family-mediated regulation of Pknox1 influences hepatic steatosis and insulin signaling. J Cell Mol Med,2018,22(12):6167-6175.
[20] Gong R, Lyu X, Liu F. MiRNA-17 encoded by the miR-17-92 cluster increases the potential for steatosis in hepatoma cells by targeting CYP7A1. Cell Mol Biol Lett,2018,23:16.

非酒精性脂肪性肝病合并2型糖尿病患者外周血miR-17、miR-20a和miR-20b变化及其临床意义^*

Changes of serum miR-17, miR-20a and miR-20b levels in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	汤磊, 邹桂舟. 外科疾病导致的胆源性肝损伤诊治现状[J]. 实用肝脏病杂志, 2021, 24(6): 769-771.
[2]	朱南南, 蒋晓红, 周佳雁, 黄小琳, 刘雅旻. 2型糖尿病合并代谢相关性脂肪性肝病患者血尿酸水平变化和其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(6): 839-842.
[3]	邢莉, 杜倩影, 姜艳丽, 韩冬. 分段注射对比剂CT增强扫描提高乙型肝炎肝硬化患者肝静脉显影效果研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 871-874.
[4]	吴慧娟, 何年安, 谢蠡, 叶显俊, 章生龙, 刘力. 超声造影联合血清CA19-9鉴别诊断胆管细胞癌与肝细胞癌应用研究[J]. 实用肝脏病杂志, 2021, 24(6): 903-906.
[5]	周正, 刘玮. 肝血管瘤、肝细胞癌和肝血管平滑肌脂肪瘤超声造影特点观察^*[J]. 实用肝脏病杂志, 2021, 24(6): 911-914.
[6]	武琼, 孙洋, 刘娜, 张锦. 失代偿期肝硬化并发败血症患者外周血白细胞VCS参数变化及其临床价值分析[J]. 实用肝脏病杂志, 2021, 24(5): 633-636.
[7]	王利公, 赵珊, 白凯, 张宁, 张楠. 慢性乙型肝炎患者血清α1酸性糖蛋白、α1-抗胰蛋白酶和触珠蛋白变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(5): 673-676.
[8]	杨永汉, 路萍, 孟庆宁, 张枫婕. 增强MRI T1 mapping定量评估慢性乙型肝炎患者肝纤维化程度效能分析[J]. 实用肝脏病杂志, 2021, 24(5): 685-688.
[9]	黄霜湘, 姚朝光, 蓝婧, 欧琴, 覃冬林, 陈丽芬, 黄洁婕. 慢加急性乙型肝炎肝衰竭患者血清自噬相关蛋白水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(5): 721-724.
[10]	梁旭, 刘圆圆, 杨学刚, 任静. 基于2018年版肝脏影像报告数据系统对比分析CT和MRI诊断肝细胞癌的效能^*[J]. 实用肝脏病杂志, 2021, 24(5): 725-728.
[11]	张武花, 栗海龙, 秦启斌, 史纲. CT自动管电流调节联合自适应迭代算法技术诊断肝血管瘤价值分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 749-752.
[12]	徐燕, 李啸天, 刘慧, 陈渝晖. 管壁增厚型胆囊癌患者MRI影像学特征分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 757-760.
[13]	孙海荣, 冯伟广, 周冰清, 刘慧敏, 蒋蓓莉. 不同血清ALT水平的乙型肝炎病毒感染者肝纤维化指标变化[J]. 实用肝脏病杂志, 2021, 24(4): 488-491.
[14]	安红杰, 徐金凤, 耿华, 葛志胜, 何文艳, 赵崇山, 高美丽, 陈俊, 周东方. FibroScan行肝脏硬度检测和APRI评估慢性丙型肝炎患者肝纤维化程度价值比较^*[J]. 实用肝脏病杂志, 2021, 24(4): 492-495.
[15]	王嘉妮, 刘湧, 周忻, 任传路, 缪惠锴. 慢性丙型肝炎患者血清microRNA-1273g-3p水平预测肝硬化价值分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 496-499.